WT1 and acute myeloid leukemia: Comparable to above-average AML control in patient #1, #3 and #5 with OS rates of > 82, 30 and 72 months, long-term remission of more than 8 years was described in one AML patient treated with WT1 peptide vaccine by Tsuboi et al. [27].